Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …

Background Biochemical recurrence (BCR) following primary interventional treatment
occurs in approximately one-third of patients with prostate cancer (PCa). Next-generation …

Background and objective Advances in molecular diagnostics have ushered in a new era for
patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular …

中国初诊的前列腺癌患者中40%~ 70% 已处于转移性疾病阶段, 而前列腺癌发生,
发展的时空异质性及独特的转移模式使得基于活检组织取材分析免疫标志物的方式困难重重 …

Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …

Prostate cancer (PCa) is the most common cancer diagnosed in men in most developed
countries and a leading cause of cancer-related morbidity and mortality. Prostate-specific …

Background: treated prostate cancer (PCa) patients develop biochemical recurrence (BCR)
in 27–53% of cases; the role of MRI in this setting is still controversial. In 2021 a panel of …

Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the
diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly …

Introduction Theranostics targeting prostate-specific membrane antigen (PSMA) represent a
new targeted approach for prostate cancer care that combines diagnostic and therapeutic …

Current US clinical practice guidelines for advanced prostate cancer management contain
recommendations based on high‐level evidence from randomized controlled trials; …